All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Gan & Lee Pharmaceuticals' Ondibta (insulin glargine) receives EU approval for diabetes mellitus treatment
Protein therapy, metabolic, insulin analog, diabetes mellitus, long-acting insulin - Read more

THE GOOD
Business Development & Partnerships

Allele Biotechnology & Pharmaceuticals, UC San Diego partner on 3D bioprinted liver project, $25.8M funding
Research collaboration, regenerative medicine, 3D bioprinting, cell therapy, manufacturing - Read more

ElpasBio, Fosun Kairos partner on AlloJoin stem cell therapy commercialization in China
Commercialization, cell therapy, stem cell, milestone payments - Read more

Pediatric Cancer Research Foundation, Oncoheroes Biosciences renew investment partnership for pediatric oncology clinical trials
Equity investment, pediatric oncology, drug development, R&D - Read more

Rakuten Medical, LOTTE Biologics sign manufacturing agreement for Alluminox photoimmunotherapy production capabilities
Manufacturing agreement, oncology, antibody, photoimmunotherapy - Read more

Alfasigma, Innovative Molecules GmbH partner on exclusive worldwide license for parenteral adibelivir treating HSV encephalitis
Licensing deal, rare disease, infectious disease, small molecule, equity investment - Read more

Genethon, AskBio sign exclusive worldwide licensing agreement for investigational gene therapy treating Pompe disease
Licensing deal, rare disease, gene therapy, Pompe disease - Read more

Jazz Pharmaceuticals sells priority review voucher from Modeyso approval for $200 million
Regulatory voucher sale, oncology, milestone payments - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Johnson & Johnson's Tecvayli (teclistamab) shows Ph3 success targeting BCMA in relapsed multiple myeloma patients
Antibody, cancer, bispecific T-cell engager, multiple myeloma, BCMA target, monotherapy - Read more

THE GOOD
Company Launches

Caldera Therapeutics launches with $112.5M funding and dual-targeting inflammatory bowel disease drug from China's Qyuns
Small molecule, autoimmune, strategic, major transaction - Read more

THE GOOD
Earnings & Finances

Bayer shares surge 6% as partner Orion forecasts strong growth for prostate-cancer drug darolutamide
Small molecule, oncology, strategic, financial - Read more

THE GOOD
Fundraises

Cedars-Sinai receives $5M ARPA-H award, developing AI-driven drug safety platform
AI/ML platform, drug safety, platform technology, preclinical - Read more

Vivere Oncotherapies raises $10M+ funding, immune-activating cancer therapies development
Cancer, immunotherapy, bioengineering platform, preclinical - Read more

Axol Bioscience raises $2.8M funding, iPSC technologies for drug discovery research
iPSC technology, drug discovery, neurological, services, platform technology - Read more

Servier launches Servier Ventures with €200M ($232.8M) fund for oncology/neurology biotechs
Pharmaceutical company, oncology, neurology, corporate venture capital - Read more

THE GOOD
Mergers & Acquisitions

Sino Biopharmaceutical to acquire Hygieia Biomedical for $172M to expand siRNA chronic disease pipeline
siRNA, chronic disease, strategic, major transaction - Read more

Charles River Laboratories acquires nonhuman primate supplier K.F. for $510M to secure animal supply chain control
Preclinical services, strategic, major transaction, operational, supply chain - Read more

THE GOOD
Regulatory

Eli Lilly expects second-quarter 2026 FDA decision on orforglipron obesity pill with priority voucher review
Small molecule, metabolic, GLP-1 receptor agonist, obesity, oral formulation - Read more

US and European regulators release 10 guiding principles for AI use in drug development process
AI drug discovery, oncology, regulatory, strategic, major transaction - Read more

THE GOOD
Strategic Plans

AstraZeneca reaffirms $80B revenue target by 2030, highlighting ADCs, cell therapies, and near-term drug launches
Antibody-drug conjugate, oncology, strategic, financial - Read more

Eli Lilly outlines strategy to dominate obesity market against Novo Nordisk and emerging rivals like Pfizer, Roche
GLP-1 agonist, obesity, strategic, competitive - Read more

Novo Nordisk refocuses core business on diabetes and obesity, pulling back from unrelated indications
GLP-1 agonist, diabetes, obesity, strategic, competitive - Read more

AbbVie plans obesity market expansion using licensed amylin-based weight-loss drug GUBamy from Gubra
Amylin agonist, obesity, strategic, competitive - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Layoffs

Thermo Fisher to lay off 421 workers, wind down North Carolina lab products facility by 2026
Laboratory products, operational, cost reduction, strategic - Read more

THE BAD
Politics & Policy

Pfizer CEO Bourla urges US reforms over protectionism to compete with China's growing pharmaceutical influence
Strategic, competitive, operational, investment - Read more [Paywall]

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here